

A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients

Lynda C. Schneider, MD,* Rima Rachid, MD,* Jennifer LeBovidge, PhD, Emily Blood, PhD, Mudita Mittal, MD, and Dale T. Umetsu, MD, PhD *Boston, Mass*

Background: Peanut allergy is a major public health problem that affects 1% of the population and has no effective therapy. **Objective:** To examine the safety and efficacy of oral desensitization in peanut-allergic children in combination with a brief course of anti-IgE mAb (omalizumab [Xolair]). **Methods:** We performed oral peanut desensitization in peanut-allergic children at high risk for developing significant peanut-induced allergic reactions. Omalizumab was administered before and during oral peanut desensitization. **Results:** We enrolled 13 children (median age, 10 years), with a median peanut-specific IgE level of 229 kU_A/L and a median total serum IgE level of 621 kU/L, who failed an initial double-blind placebo-controlled food challenge at peanut flour doses of 100 mg or less. After pretreatment with omalizumab, all 13 subjects tolerated the initial 11 desensitization doses given on the first day, including the maximum dose of 500 mg peanut flour (cumulative dose, 992 mg, equivalent to >2 peanuts), requiring minimal or no rescue therapy. Twelve subjects then reached the maximum maintenance dose of 4000 mg peanut flour per day in a median time of 8 weeks, at which point omalizumab was discontinued. All 12 subjects continued on 4000 mg peanut flour per day and subsequently tolerated a

challenge with 8000 mg peanut flour (equivalent to about 20 peanuts), or 160 to 400 times the dose tolerated before desensitization. During the study, 6 of the 13 subjects experienced mild or no allergic reactions, 5 subjects had grade 2 reactions, and 2 subjects had grade 3 reactions, all of which responded rapidly to treatment.

Conclusions: Among children with high-risk peanut allergy, treatment with omalizumab may facilitate rapid oral desensitization and qualitatively improve the desensitization process. (*J Allergy Clin Immunol* 2013;132:1368-74.)

Key words: Oral immunotherapy, desensitization, food allergy, peanut allergy, omalizumab

Discuss this article on the JACI Journal Club blog: www.jaci-online.blogspot.com.

Food allergy is a major public health problem that affects a large proportion of the general population in industrialized countries, estimated to include 3% to 4% of the US population.^{1,2} While many different foods cause allergy, peanut is one of the more common foods causing allergy.³⁻⁵ Furthermore, reactions to peanuts and tree nuts account for a disproportionate number of severe reactions (94% of fatalities) from food allergy.^{3,6} In addition, accidental ingestion of peanuts occurs in up to 25% to 75% of patients over a 5-year period, despite strict dietary avoidance measures, resulting in significant anxiety for many patients and families of children with peanut allergy.⁷ Moreover, while sensitivity to other common foods such as milk and soy often resolves spontaneously over time, sensitivity to peanut more commonly fails to diminish.⁸ Unfortunately for patients with food allergy, no effective treatment is currently available except to avoid offending foods and to have ready access to self-injectable epinephrine.¹

Recently, there have been reports of success in several clinical trials of oral food allergen immunotherapy/desensitization for milk,⁹⁻¹¹ egg,^{12,13} peanut,¹⁴⁻¹⁶ and hazelnut.¹⁷ The protocols for desensitization are varied, involving rush therapy phases,¹¹ weekly increases in dose over many months⁹ or both,^{10,12} and using oral and/or sublingual approaches.^{17,18} Double-blind, placebo-controlled food challenges (DBPCFCs) at the conclusion of these studies demonstrated that most patients tolerated more food protein than at study onset and that long-term, safe daily intake of the food could be achieved in many patients.^{19,20} However, mild to severe clinical symptoms including anaphylaxis occurred in most patients during the desensitization, greatly limiting the utility of this procedure. In addition, 10% to 25% of the patients had severe reactions, particularly those with high peanut-specific IgE levels, and may be refractory to oral desensitization.^{10,21-23} Furthermore, many of the studies focused on

From Boston Children's Hospital and Harvard Medical School.

*These authors contributed equally to this work.

This study was funded by the Thrasher Research Foundation, the Clinical and Translational Science Center/Harvard Catalyst (NIH UL1 RR 025758), the Food Allergy Initiative, the Dave and Denise Bunning Food Allergy Project, the Jasmine and Paul Mashikian Fund, and Genentech.

Disclosure of potential conflict of interest: L. C. Schneider has received research support from the Thrasher Foundation and the Bunning Food Allergy Fund, received omalizumab for the study from Genentech, and is a member of the Scientific Advisory Board for Food Allergy Research and Education. R. Rachid has received grants from the Thrasher Fund Foundation, the Clinical and Translational Science Center/Harvard Catalyst, the Food Allergy Initiative, the Bunning Food Allergy Project, the Jasmine and Paul Mashikian Fund, Genentech, and CSL Behring. J. LeBovidge is a board member for the New England Chapter of the Asthma and Allergy Foundation of America and has received payment for the development of educational presentations from Anaphylaxis Canada. D. T. Umetsu has received grants from the Thrasher Foundation, Genentech, the National Institutes of Health, and Food Allergy Research and Education; has consultant arrangements with Innate Immune, Inc; has patents with and receives royalties from Stanford University and Boston Children's Hospital; and has received travel support from the University of Pennsylvania, the University of California-Davis, the American Thoracic Society, the World Allergy Organization, the Research Center for Allergy and Immunology, and the Japanese Society of Allergology. The rest of the authors declare that they have no relevant conflicts of interest.

Received for publication September 5, 2013; revised September 26, 2013; accepted for publication September 26, 2013.

Available online October 28, 2013.

Corresponding author: Dale T. Umetsu, MD, PhD, Karp Laboratories, Rm 10127, One Blackfan Circle, Boston, MA 02115. E-mail: dale.umetsu@gmail.com. 0091-6749/\$36.00

© 2013 American Academy of Allergy, Asthma & Immunology
<http://dx.doi.org/10.1016/j.jaci.2013.09.046>

Abbreviation used

DBPCFC: Double-blind, placebo-controlled food challenge

reducing the severity of reactions on accidental ingestion rather than on adding normal dietary quantities of the food to the diet. Nevertheless, these studies demonstrate that oral food desensitization might be a useful method for treating food-allergic patients to increase the threshold for food tolerance and possibly to hasten the resolution of food allergy.

We hypothesized that oral desensitization might occur more rapidly and with greater success using anti-IgE mAb (omalizumab [Xolair] Genentech, Inc, South San Francisco, Calif) as pretreatment before and during oral food desensitization. Omalizumab is a humanized mAb that binds free IgE, thereby inhibiting allergic reactions, and is approved by the Food and Drug Administration for use in older children and adults with moderate to severe allergic asthma.²⁴ Omalizumab and a related anti-IgE mAb, TNX-901, have been used in patients with peanut allergy and have been shown to significantly increase the threshold of sensitivity to peanut on oral peanut challenge^{25,26}; however, these studies did not assess the role of anti-IgE mAb therapy in enhancing oral desensitization to peanuts. Recently, we showed in a pilot safety study that omalizumab pretreatment before rapid oral desensitization in children with significant milk allergy was safe, and may have facilitated oral desensitization.²⁷⁻²⁹ These results suggested that such an approach might be effective for oral desensitization in patients with peanut allergy at high risk for developing allergic reactions even with trace amounts of peanuts. Indeed, we herein demonstrate that a short 20-week course of omalizumab in peanut-allergic children at high risk for developing significant peanut-induced allergic reactions was effective in facilitating rapid and successful oral peanut desensitization.

METHODS

Study population

The inclusion criteria for this study were as follows: patients with peanut allergy, between the ages of 7 and 25 years with a history of significant clinical symptoms (generalized urticaria, vomiting, and/or anaphylaxis) within 1 hour of peanut ingestion; peanut-specific IgE level of more than 20 kU/L; total IgE level of more than 50 kU/L but less than 2000 kU/L; and positive skin prick test result to peanut extract (>6 mm wheal). Patients also had to fail a DBPCFC with peanut at a dose of 100 mg or less of peanut flour (cumulative dose of ≤ 186 mg) (light roasted peanut flour; Golden Peanut Company, Alpharetta, Ga), with no reactions to the placebo challenge. The exclusion criteria included the presence of significant medical disease such as infections, autoimmune disease, and cardiac disease and treatment with beta-adrenergic antagonistic drugs. Subjects having a history of anaphylaxis to peanut requiring intubation, chronic urticaria, severe eczema, poorly controlled persistent asthma, gastrointestinal or gastroesophageal disease, and non-IgE-mediated food allergy (eosinophilic esophagitis, eosinophilic enteritis, proctocolitis, food protein-induced enterocolitis syndrome) were also excluded.

Thirteen patients with a history of IgE-mediated peanut allergy with a high risk for developing significant peanut-induced allergic reactions were enrolled. The median age of the patients at enrollment was 10 years (range, 8-16 years) (Table 1). The subjects included 8 boys and 5 girls. Six of the 13 patients had a past or current history of eczema, asthma, or both, 6 had a history of at least 1 other food allergy, and 4 had 2 or more additional food allergies. All the children had skin prick test wheal responses of more than 8.5 mm (mean of the longest diameter and the longest orthogonal width) to peanut extract; the median peanut-specific IgE level was 229 kU_A/L (Phadia

ImmunoCAP System, Portage, Mich). The Institutional Review Board at Boston Children's Hospital approved the clinical protocol, and all participants and their parents provided written informed assent and consent, respectively.

Design

Patients were treated with omalizumab by using European dosing guidelines based on weight and serum total IgE level³⁰ for 12 weeks to minimize the IgE bound to FcεR1 on mast cells and basophils³¹ (Fig 1). In week 12, patients were admitted to the Clinical and Translational Study Unit for initiation of oral desensitization. Eleven doses (0.1, 0.5, 1.5, 3, 7, 15, 30, 60, 125, 250, and 500 mg; cumulative dose, 992 mg peanut flour) were administered over a period of 6 hours. Clinical research pharmacists prepared all doses. After the rush desensitization, all subjects returned the next day to the Clinical and Translational Study Unit to start the slower up-dosing escalation phase, beginning at 500 mg peanut flour. Subjects received subsequent doses at home for the next 6 days and were instructed not to exceed the specifically assigned doses at home, not to consume other peanut-containing products, and not to introduce any new foods to the child's diet. Premeasured doses were provided to all participants, who were required to have diphenhydramine and self-injectable epinephrine available at all times. Home diary forms were provided to record the dose date, time taken, symptoms occurring after the dose or any other time, and medications taken each day. For the next 8 weeks (weeks 12-20), the subjects returned weekly for each increase in the daily oral dose to a dose of 4000 mg peanut flour (doses, 750, 1000, 1250, 1600, 2000, 2600, 3250, and 4000 mg peanut flour). At week 20, after subjects reached the 4000 mg daily dose, omalizumab was discontinued, but daily oral peanut dosing continued.

A second DBPCFC was conducted 12 weeks after discontinuing the omalizumab (approximately week 32 of the study, and after 4 elimination half-lives of omalizumab). The challenge consisted of 5 doses (peanut or placebo, administered orally every 15 minutes, 500, 750, 1250, 2000, and 3500 mg; cumulative dose 8000 mg peanut flour, equivalent to about 20 peanuts). If the subject passed the DBPCFC, an open challenge of 8000 mg peanut flour was given 16 hours later. Allergic reactions occurring during the protocol were scored by using the system developed by Bock³² (see the Appendix in this article's Online Repository at www.jacionline.org). After the DBPCFC, subjects continued on 10 to 20 daily peanuts orally per day.

Registration

This trial was registered on ClinicalTrials.gov (NCT01290913).

Statistical analysis

Statistical analysis is largely descriptive. Two-sided 95% CIs for percentages were calculated by using the exact binomial method. When the observed percentage was 100%, we report a 1-sided 97.5% CI instead.

RESULTS

Pretreatment DBPCFC

During the screening DBPCFC, all 13 subjects who eventually enrolled developed significant allergic symptoms including anaphylaxis (6 requiring epinephrine). During this initial DBPCFC, the patients who enrolled developed symptoms at a peanut flour dose of 100 mg or less (approximately ¼ peanut) (median dose, 50 mg peanut flour) (Table 1). Peanut flour contains approximately 50% peanut protein.

Oral desensitization

On enrollment, all subjects received omalizumab every 2 or 4 weeks for 12 weeks, based on modified Genentech dosing guidelines. Subjects were then admitted to the Clinical and Translational Study Unit for oral desensitization, starting at 0.1 mg peanut flour and reaching a top dose of 500 mg peanut flour

TABLE I. Characteristics of enrolled subjects

Subject no.	Age (y)	Sex	Total IgE level (kU/L)	Peanut-specific IgE level (kU _A /L)*	Peanut skin test wheal (mm)/† erythema (mm)	Dose (peanut flour) failed DBPCFC (mg)‡	Omalizumab dose and frequency	Total doses of omalizumab
1	8	M	1786	436	12.5/37	100	450 mg every 2 wk	10
2	8	M	276	58	20.5/46	50	225 mg every 4 wk	6
3	9	F	1524	617	15/25.5	100	600 mg every 2 wk	10
4	15	M	485	84	18/37.5	1	300 mg every 2 wk	9
5	14	M	621	150	16.5/47.5	100	300 mg every 2 wk	10
6	14	M	981	229	10.5/38.5	100	525 mg every 2 wk	11
7	8	M	698	378	19/42.5	50	225 mg every 2 wk	11
8	14	F	571	290	24/47.5	100	300 mg every 2wk	13
9	7	M	169	65	9.5/25	20	150 mg every 4 wk	6
10	10	F	735	327	9.5/35.5	50	300 mg every 2 wk	11
11	11	F	106	21	8.5/30	50	150 mg every 4 wk	6
12	12	F	630	307	24.5/57	100	225 mg every 2 wk	10
13	8	M	389	172	18/37	20	225 mg every 4wk	6
Median	10		621	229	16.5/37.5	50	NA	10

None of the subjects carried a diagnosis of eosinophilic esophagitis at screening and during the course of the study.


Entry criteria: Children aged 7 to 25 years with peanut-specific IgE level of more than 20 kU_A/L and total IgE level of less than 2000 kU/L; with significant clinical history of IgE-mediated peanut allergy, but without history of intubation, severe asthma, immunotherapy or biologic therapy, and without a medical diagnosis of non-IgE-mediated eosinophilic disease.

F, Female; M, male; NA, not applicable.

*Normal value (<0.35 kU_A/L).

†Mean of the longest diameter and the longest orthogonal width.

‡Peanut flour is approximately 50% peanut protein.

**FIG 1.** Protocol flow chart.

within 6 hours. All 13 subjects (100%) reached the 500 mg peanut flour dose on the first day (cumulative dose, 992 mg), which was the primary outcome of the study, with minimal or no symptoms

(97.5% CI, 75.3% to 100%). Over the next 7 to 12 weeks, the daily oral peanut dose was increased from 500 mg to 4000 mg. Twelve of the 13 children (92%) reached the 4000 mg dose (95% CI, 64% to 99.8%), which was a secondary outcome of the study, requiring a median time of 8 weeks to reach this dose. One subject withdrew at week 15 after developing persistent nausea and vomiting associated with increased oral mucus production after reaching the 1250 mg dose. In the remaining 12 subjects, omalizumab treatment was discontinued after the 4000 mg dose of peanut was achieved. All 12 subjects continued daily peanut dosing (≥ 4000 mg peanut flour per day) for the rest of the study.

Twelve weeks after stopping omalizumab (week 32), the 12 subjects underwent a DBPCFC (cumulative dose, 8000 mg peanut flour). Eleven of the subjects (85%) (95% CI, 54.6% to 98.1%) tolerated this challenge, but 1 subject vomited once after receiving the highest dose (3500 mg; cumulative dose, 8000 mg). However, this subject later passed an open challenge of 8000 mg peanut flour. Therefore, 12 of the 13 subjects (92%) tolerated an 8000 mg dose of peanut flour (equivalent to approximately 20 peanuts). Following the DBPCFC, these subjects continued taking 10 to 20 peanuts daily until the end of the study at week 52.

Reactions/safety data

All symptoms including minor ones that occurred during the course of the desensitization were recorded, using the scoring system of Bock,³² although in many instances the exact cause of the symptoms was not clear. For example, symptoms such as vomiting or wheezing were thought in several instances to be due to viral infection. Viral gastroenteritis was diagnosed clinically in at least 3 patients (as deduced by the presence of gastroenteritis symptoms in multiple family and community contacts), although symptoms may have been worsened by peanut ingestion. During this time, the dose of peanut was reduced or held for 1 to 2 days because tolerance to peanut might be reduced during viral infection.³³ Difficulty in tolerating the taste of the

peanut flour was also common in our patients, likely contributing to some of the nausea and vomiting, particularly with higher doses. In 2 subjects, swallowing the peanut flour in capsules rather than eating it mixed in with other foods alleviated some of these symptoms, suggesting that aversion to the taste of peanut flour was a significant issue in these patients. Finally, anxiety from having to ingest a food that was assiduously avoided in the past may have exacerbated allergy symptoms in many of our patients.

We recorded a total of 72 reactions during the study (2.0% of the 3502 total peanut doses ingested) (0-25 reactions per subject) (Table II). Twenty-five of the reactions occurred in 1 subject (patient 006), who also had a history of supraventricular tachycardia; most of these reactions were episodes of nausea and hypersalivation lasting 15 to 20 seconds and did not require treatment. In the other subjects, most of the reactions were also mild (grade 1 or 2) and were easily treated by observation or with oral H1 and H2 antihistamines. Importantly, 6 of the 13 subjects (46%) had no or a single grade 1 allergic reaction; 3 subjects (23%) had no allergic reaction during the study (Table III). Six of the 13 patients (39%) experienced a grade 2 or 3 adverse event (Table III); 2 grade 3 reactions occurred during the maintenance phase (see later), and all reactions responded rapidly to treatment. All subjects tolerated omalizumab without adverse reactions, except for occasional injection site pain and swelling.

During the first day of desensitization, 7 of the 13 subjects (54%) tolerated a cumulative peanut dose, 992 mg with no reactions; the remaining 6 subjects developed grade 1 reactions (2 of these patients were treated with antihistamines) (Tables II and III). During this first day of desensitization, no subject developed a grade 2 or grade 3 reaction. During the up-dosing phase, when the dose was increased weekly from 500 mg to 4000 mg peanut flour, 49 reactions were recorded (96% of these were grade 1, and 4% were grade 2), and most reactions were easily controlled with antihistamines. The most common reactions were nausea and salivation, or abdominal pain, occurring in 7 patients (54%). Because of these symptoms, 5 patients (42%) were placed on maintenance H1 and H2 antihistamines. One patient (006), who had the history of supraventricular tachycardia, developed nausea, lightheadedness, and hypersalivation after a 1250 mg dose and received epinephrine at home for a grade 2 reaction. Another patient (004) withdrew from the study at the 15-week time point because of persistent nausea, vomiting, and hypersalivation after reaching the 1250 mg dose.

After reaching the 4000 mg maintenance dose, and after discontinuing omalizumab, the subjects were followed for an additional 6-month maintenance period, during which time there were 17 recorded reactions (10 grade 1; 5 grade 2; and 2 grade 3), with 2 subjects receiving epinephrine at home. Patient 008 received epinephrine for vomiting, diarrhea, and wheezing (grade 3 reaction) 2.5 hours after peanut dosing, possibly worsened by known triggers of reactions, including concomitant infection, menstruation, naproxen (nonsteroidal anti-inflammatory drug) use, or school-associated stress.³³ Patient 007 received epinephrine on 3 occasions for grade 2 reactions: the first time, several days after passing the second DBPCFC, the second time in week 36, and a third time in week 42. On all these occasions, the reactions of coughing, hives, and wheezing were associated with exercise, which is known to trigger symptoms following the ingestion of a previously tolerated dose.^{20,23} Because these episodes were unpredictable

TABLE II. Overall safety data

Symptom	No. (% of total doses)	No. of reactions per child, mean (range)
Total peanut doses		3502
Peanut doses per child, mean (range)		269 (31-295)
Total reactions	72 (2.0%)	5.53 (0-25)
Grade 1 (Mild) symptoms	63 (1.8%)	4.8 (0-25)
On rush desensitization day	6	0.46 (0-1)
During weekly dosing escalation phase	47	3.6 (0-18)
During maintenance dosing	10	0.83 (0-5)
Grade 2 (Moderate) symptoms	7 (0.2%)	0.53 (0-7)
On rush desensitization day	0	0
During weekly dosing escalation phase	2	0.15 (0-1)
During maintenance dosing	5	0.42 (0-2)
Grade 3 (Severe) symptoms	2 (0.06%)	0.17 (0-1)
On rush desensitization day	0	0
During weekly dosing escalation phase	0	0
During maintenance dosing	2	0.17 (0-1)

Total number of subjects = 13.

Reactions were graded by using scores defined by Bock.³²

and resulted in considerable anxiety, the family decided to withdraw from the study.

DISCUSSION

The results of our study suggest that pretreatment with omalizumab may facilitate rapid oral desensitization in peanut-allergic subjects at high risk for developing significant peanut-induced allergic reactions on exposure to even small amounts of peanut. Significant peanut allergy was confirmed by failing an initial DBPCFC after a median dose of 50 mg peanut flour. After receiving omalizumab, all the 13 subjects tolerated the first-day desensitization to peanut, reaching the maximum first-day desensitization dose of 500 mg peanut flour (cumulative dose, 992 mg peanut flour), with minimal or no symptoms, thus achieving the primary end point of the study. Twelve of the 13 subjects (92%) then reached the maximum 4000 mg dose over a 7- to 12-week time period (median time, 8 weeks), at which point omalizumab treatment was discontinued. All 12 subjects continued to tolerate daily oral dosing of peanut even after discontinuing omalizumab, and then tolerated an open challenge dose of 8000 mg peanut flour, a dose approximately 160 to 400 times the dose tolerated before desensitization.

Our current results extend those of a previous small study of oral desensitization with omalizumab of high-risk, milk-allergic patients, in which 9 of the 11 subjects (82%) were rapidly and successfully desensitized, and were able to pass an oral challenge of 8000 mg or more of milk without symptoms. However, because an initial DBPCFC was not performed, we could not formally assess the degree of improvement in milk tolerance, although all the patients had high initial levels of milk-specific IgE (median, 50 kU_A/L; range, 42-342 kU_A/L [normal level, <0.32 kU_A/L]) and were unlikely to have spontaneously outgrown their milk allergy. Nevertheless, these studies together strongly suggest that omalizumab might facilitate oral desensitization not only with a food allergy that is frequently outgrown (milk) but also with a

TABLE III. Safety data for individual subjects

Subject no.	First-day desensitization			Up-dosing			Maintenance		
	Grade 1	Grade 2	Grade 3	Grade 1	Grade 2	Grade 3	Grade 1	Grade 2	Grade 3
001	—	—	—	—	—	—	—	—	—
003	—	—	—	—	—	—	—	—	—
005	—	—	—	—	—	—	—	—	—
011	—	—	—	1*	—	—	—	—	—
010	1	—	—	—	—	—	—	—	—
009	1	—	—	1	—	—	—	—	—
002	1	—	—	—	—	—	—	1	—
012	—	—	—	—	—	—	2	1	—
008	—	—	—	2	1	—	1	—	1
013	1	—	—	6	—	—	1	1	1
007	—	—	—	11	—	—	1	2	—
006	1	—	—	18	1	—	5	—	—
004	1	—	—	8	—	—	†	—	—
Percentage of subjects not having reactions	54	100	100	46	85	100	58	67	83

The dash (—) indicates that no reactions were observed during the indicated time period.

*Number of reactions of the indicated grade during the desensitization protocol. All patients, except 004 (left study at week 15) and 007 (left study at week 42), completed 52 weeks of the study. The DBPCFC occurred at week 32.

†Patient 004 dropped out at week 15 and was never on maintenance treatment.

food allergy that does not normally resolve spontaneously and is associated with most of the fatalities (peanut).

In our current study, we intentionally focused on patients with high levels of peanut-specific IgE levels who were at high risk for developing significant peanut-induced allergic reactions. Such patients with high peanut-specific IgE levels likely have very robust peanut-specific immunity that resists change, and therefore may benefit more from omalizumab treatment. Indeed, during desensitization without omalizumab, children with higher food-specific IgE levels were more likely to fail egg desensitization²² or were unable to tolerate high doses of peanut after rush desensitization.²¹ Nevertheless, oral desensitization without omalizumab can be successful in patients with peanut, milk, egg, and hazelnut allergy.^{12,14-17,34-36} However, in all these studies, a common theme was the high rate of significant reactions, with 10% to 30% having severe reactions and being refractory to oral desensitization, particularly in those with high food-specific IgE levels,^{10,21-23} resulting in lengthy desensitization periods, varying from many months to years.

In contrast, after treatment with omalizumab, our patients, who had the highest median peanut-specific IgE level of any previous study of peanut desensitization that we know of, were all able to tolerate much higher doses of peanut in much shorter periods of time. Thus, all the 13 patients progressed within 1 day to a maximum dose of 500 mg peanut flour (cumulative dose, 992 mg). In comparison, in an oral desensitization study without omalizumab, on the initial day of desensitization, only 10 of the 39 subjects (26%) tolerated a cumulative dose equivalent to 200 mg peanut flour³⁴; in another study, only 6 of the 28 subjects (21%) tolerated a cumulative dose equivalent to 200 mg peanut flour.¹⁶ A post hoc comparison showed that these 2 rates were significantly different from our results, with a *P* value of less than .0001 (Fisher exact test), even though the maximum cumulative dose in our study was 3 times higher than in the previous 2 studies. Because of the high frequency of allergic reactions associated with oral desensitization without omalizumab, more recent studies have limited the maximum dose on the first day to a cumulative dose equivalent to 24 mg peanut

flour.^{36,37} Finally, with omalizumab treatment, our patients required a median time of only 8 weeks to reach a maintenance dose of 4000 mg peanut flour, whereas in a previous peanut desensitization study without omalizumab the median time for 14 subjects to reach doses of 500 to 2000 mg of peanut was 30 weeks,²¹ and in another study the median time for 19 subjects to reach a dose equivalent to 1600 mg peanut flour was 20 weeks.²³ The rapidity of reaching maintenance desensitization dosing in our study compared with previous studies is remarkable, particularly given the much higher peanut-specific IgE levels in our patient population and our low failure rate.

Over the course of our study, 2.0% of the doses were associated with reactions, and most of these were grade 1 or grade 2, and easily controlled with antihistamines. As noted earlier, on the first day of desensitization, 100% of our patients tolerated a cumulative dose of 992 mg peanut flour, with 7 having no reactions at all and 6 patients having grade 1 reactions (2 treated with antihistamines) (Table III). Although the goal of our protocol was to allow peanut-allergic patients to tolerate ingestion of 10 to 20 peanuts, the fact that all our subjects tolerated 992 mg peanut flour after only 1 day of desensitization suggests that 1 day of desensitization might protect a patient against anaphylaxis associated with accidental exposure, a major concern among patients and their families. In addition, because omalizumab neutralizes IgE of all specificities, our result with peanut suggests that rapid desensitization to other foods, either singly or simultaneously, may be achievable in a short period of time.

During the weekly up-dosing phase, 6 of the 13 patients (46%) had no reactions and 2 additional patients (15%) had only minor reactions that did not require treatment. Only 1 patient (patient 006) received epinephrine during the up-dosing period for a grade 2 home reaction that may not have required epinephrine. Attributing a cause for these reactions was not always straightforward because many of the symptoms could have been caused by concomitant viral infections, which caused vomiting and sometimes wheezing, and which slowed the progress of dose escalation (Norovirus infection was particularly common in the community during the study). In addition, in some

patients, intolerance of the taste of peanut flour appeared to cause nausea and excessive salivation because these symptoms improved when the peanut flour was swallowed in capsules rather than mixed in food. Nevertheless, these results demonstrate that when the subjects were on omalizumab, allergic reactions during the relatively rapid desensitization process were surprisingly mild.

During the maintenance phase (weeks 20-52, Fig 1), after omalizumab was stopped and when patients took a daily dose of 4000 mg peanut flour, 6 of the 12 patients (50%) had no reactions and 3 others (25%) had only minor grade 1 or 2 reactions. However, 2 other patients (17%) required epinephrine treatment, receiving it at home. One patient (008) received epinephrine in the setting of a viral illness, menstruation, or with nonsteroidal anti-inflammatory drug use, and possible school-related stress, even after she had tolerated multiple 4000 mg doses of peanut and the second DBPCFC. These reactions all occurred more than 2 hours after the peanut dose. The second patient (007) received epinephrine on 3 occasions after passing the second DBPCFC for reactions associated with exercise. All the episodes were associated with specific triggers (infection, exercise, menstruation, or nonsteroidal anti-inflammatory drug use) and were all easily controlled. We speculate that the frequency of these reactions might be reduced by a longer treatment period with omalizumab, particularly because the peanut-specific IgE levels, which were very high before treatment, were still high even at week 52, when the median peanut-specific IgE level was 70 kU_A/L. This idea is also supported by the fact that the median initial peanut skin test wheal size (Tables I and III) in the 7 patients who had more frequent and severe reactions (median wheal size = 19 mm) was significantly greater than that in the 6 patients who had no or grade 1 reactions (median wheal size = 11 mm) (Wilcoxon rank sum test, $P = .03$).

The persistence of high levels of peanut-specific IgE in our subjects on maintenance therapy suggests that peanut-specific immunity was robust in our patients and that long-term oral maintenance dosing may be required to drive down peanut-specific IgE levels to “nonallergic” levels. This idea might be consistent with the results of a recent study showing that only 28% of orally desensitized egg-allergic patients developed “immunological tolerance,” as defined by the ability of egg-desensitized patients to avoid egg for 2 months and still pass an oral egg challenge,¹³ and suggests that the development of “immunological tolerance” after oral desensitization may require long periods of oral therapy. Currently, our recommendation to our study patients who tolerate doses of 10 to 20 peanuts is to remain on daily peanut dosing until peanut-specific IgE levels fall well below the initial levels, which may take many more months. We anticipate that tolerance of peanuts will improve over time on maintenance treatment, but we are being vigilant for complications, including eosinophilic esophagitis, which has been reported after oral desensitization.³⁸

The major limitations of our study include the small sample size and the absence of a placebo group. However, our results, using omalizumab in oral peanut desensitization, are qualitatively distinct compared with previous studies of oral desensitization without omalizumab. As noted earlier, on the initial day of desensitization, 100% of our subjects tolerated a cumulative dose of 992 mg peanut flour with minimal symptoms, whereas in several other studies without

omalizumab, 26% or less of the subjects tolerated the equivalent of 200 mg of peanut flour.^{16,34}

In conclusion, our study suggests that omalizumab may facilitate rapid oral desensitization in high-risk peanut-allergic patients with high peanut-specific IgE levels. All the patients tolerated a cumulative dose of 992 mg peanut flour on the first day of desensitization, and 92% were able to rapidly tolerate doses of 8000 mg peanut flour. Although we cannot yet recommend omalizumab to facilitate oral desensitization, our results provide strong evidence that omalizumab can effectively reduce allergic reactions and expedite successful and rapid oral peanut desensitization in patients with high peanut-specific IgE levels. Larger randomized placebo-controlled studies are currently being conducted to confirm a beneficial role of omalizumab in facilitating oral peanut desensitization.

We thank the Thrasher Research Foundation, the Clinical and Translational Science Center/Harvard Catalyst (NIH UL1 RR 025758), the Food Allergy Initiative, the Bunning Food Allergy Project, the Jasmine and Paul Mashikian Fund, and Genentech for support. Genentech was not involved in the design, implementation, or conduct of this study. We also thank members of our Data and Safety Monitoring Board, Drs Hans Oettgen, Francisco Bonilla, and Doug McDonald for their unstinting help; Drs Michael Young and Frank Twarog for referring their patients for this study; Dr Michael Young for critically reviewing the manuscript; Drs Leslie A. Kalish and Dionne Graham for help with the statistical analysis; Dr Michael Pistiner and Tim Harrington for helping with the study; and our patients, who courageously participated in this study.

Clinical implications: If confirmed with larger double-blind placebo-controlled studies, this approach using omalizumab to facilitate oral desensitization could change the clinical approach for a large number of patients with clinically significant peanut allergy.

REFERENCES

1. Sicherer SH, Sampson HA. Food allergy. *J Allergy Clin Immunol* 2010;125: S116-25.
2. Lack G. Clinical practice. Food allergy. *N Engl J Med* 2008;359:1252-60.
3. Burks AW. Peanut allergy. *Lancet* 2008;371:1538-46.
4. Lack G, Fox D, Northstone K, Golding J. Factors associated with the development of peanut allergy in childhood. *N Engl J Med* 2003;348:977-85.
5. Sicherer SH, Munoz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. *J Allergy Clin Immunol* 2010;125:1322-6.
6. Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. *J Allergy Clin Immunol* 2001;107:191-3.
7. Cummings AJ, Knibb RC, King RM, Lucas JS. The psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families: a review. *Allergy* 2010;65:933-45.
8. Fleischer DM, Conover-Walker MK, Christie L, Burks AW, Wood RA. The natural progression of peanut allergy: resolution and the possibility of recurrence. *J Allergy Clin Immunol* 2003;112:183-9.
9. Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE-mediated cow's milk allergy. *Allergy* 2004;59: 980-7.
10. Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A, Ronfani L, et al. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. *J Allergy Clin Immunol* 2008;121:343-7.
11. Staden U, Blumchen K, Blankenstein N, Dannenberg N, Ulbricht H, Dobberstein K, et al. Rush oral immunotherapy in children with persistent cow's milk allergy. *J Allergy Clin Immunol* 2008;122:418-9.
12. Buchanan AD, Green TD, Jones SM, Scurlock AM, Christie L, Althage KA, et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. *J Allergy Clin Immunol* 2007;119:199-205.

13. Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, et al. Oral immunotherapy for treatment of egg allergy in children. *N Engl J Med* 2012; 367:233-43.
14. Nash S, Steele P, Kamilaris J, Pons L, Kulis M, Lee L, et al. Oral peanut immunotherapy for children with peanut allergy. *J Allergy Clin Immunol* 2008;121:S147.
15. Clark AT, Islam S, King Y, Deighton J, Anagnostou K, Ewan PW. Successful oral tolerance induction in severe peanut allergy. *Allergy* 2009;64:1218-20.
16. Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Likhnygina Y, Steele PH, et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. *J Allergy Clin Immunol* 2009;124:286-91, 291.e1-6.
17. Enrique E, Pineda F, Malek T, Bartra J, Basagana M, Tella R, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. *J Allergy Clin Immunol* 2005;116:1073-9.
18. Keet CA, Frischmeyer-Guerrero PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. *J Allergy Clin Immunol* 2012;129:448-55, 455.e1-5.
19. Calvani M, Giorgio V, Miceli Sopo S. Specific oral tolerance induction for food: a systematic review. *Eur Ann Allergy Clin Immunol* 2010;42:11-9.
20. Sampson H. Peanut oral immunotherapy: is it ready for clinical practice? *J Allergy Clin Immunol Pract* 2013;1:15-21.
21. Blumchen K, Ulbricht H, Staden U, Dobberstein K, Beschoner J, de Oliveira LC, et al. Oral peanut immunotherapy in children with peanut anaphylaxis. *J Allergy Clin Immunol* 2010;126:83-91.e1.
22. Meglio P, Giampietro PG, Carello R, Gabriele I, Avitabile S, Galli E. Oral food desensitization in children with IgE-mediated hen's egg allergy: a new protocol with raw hen's egg. *Pediatr Allergy Immunol* 2013;24:75-83.
23. Anagnostou K, Clark A, King Y, Islam S, Deighton J, Ewan P. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. *Clin Exp Allergy* 2011;41:1273-81.
24. Fanta CH. Asthma. *N Engl J Med* 2009;360:1002-14.
25. Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH, et al. Effect of anti-IgE therapy in patients with peanut allergy. *N Engl J Med* 2003; 348:986-93.
26. Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM, et al. A phase II, randomized, double-blind, parallel group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. *J Allergy Clin Immunol* 2011;127:1309-10.e1.
27. Nadeau K, Schneider L, Hoyte E, Borrás I, Umetsu D. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. *J Allergy Clin Immunol* 2011;127:1722-4.
28. Nadeau KC, Kohli A, Iyengar S, DeKruyff RH, Umetsu DT. Oral immunotherapy and anti-IgE antibody-adjunctive treatment for food allergy. *Immunol Allergy Clin North Am* 2012;32:111-33.
29. Bedoret D, Singh AK, Shaw V, Hoyte EG, Hamilton R, Dekruyff RH, et al. Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. *Mucosal Immunol* 2012;5:267-76.
30. Dosing, Xolair. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf. Accessed October 12, 2013.
31. MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. *J Immunol* 1997;158:1438-45.
32. Bock SA, Sampson HA, Atkins FM, Zeiger RS, Lehrer S, Sachs M, et al. Double-blind, placebo-controlled food challenge (DBPCFC) as an office procedure: a manual. *J Allergy Clin Immunol* 1988;82:986-97.
33. Nowak-Wegrzyn A, Fiocchi A. Is oral immunotherapy the cure for food allergies? *Curr Opin Allergy Clin Immunol* 2010;10:214-9.
34. Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. *J Allergy Clin Immunol* 2009;124:292-300, 300.e1-97.
35. Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. *J Allergy Clin Immunol* 2008;122: 1154-60.
36. Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. *J Allergy Clin Immunol* 2011;127: 654-60.
37. Yu GP, Weldon B, Neale-May S, Nadeau KC. The safety of peanut oral immunotherapy in peanut-allergic subjects in a single-center trial. *Int Arch Allergy Immunol* 2012;159:179-82.
38. Sanchez-Garcia S, Rodriguez Del Rio P, Escudero C, Martinez-Gomez MJ, Ibanez MD. Possible eosinophilic esophagitis induced by milk oral immunotherapy. *J Allergy Clin Immunol* 2012;129:1155-7.